Efficacy of Short-term Teriparatide for Hip Osteonecrosis

Galluccio, Felice; Matucci‐Cerinic, Marco

doi:10.3899/jrheum.160190

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In refractory cases of BME secondary to CRPS, as well as seen for hip osteonecrosis, TPT might be considered as an alternative treatment, although further confirmation is needed [11].…”

Section: Discussionmentioning

confidence: 99%

“…A first off-label use of TPT has been investigated for the treatment of aseptic bone non-unions with a good safety profile and promising preliminary result [9]. Moreover, it has been successfully applied in case of transient osteoporosis and osteonecrosis of the hip [10,11]. Among the causes of BME at the knee joint, those secondary to CRPS are less investigated, and limited treatment options are available up to date.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Short-Term Teriparatide for Bone Marrow Edema Secondary to Complex Regional Pain Syndrome: Case Reports on Efficacy After Two Years of Follow-Up

Galluccio¹,

Allam²,

Perdisa³

et al. 2020

Cureus

Self Cite

View full text Add to dashboard Cite

Bone marrow edema secondary to chronic pain syndrome after knee trauma is a disabling condition that presents with localized pain, allodynia, edema, decreased range of motion and osteopenia. The management includes a variety of medications and rehabilitation. The treatment of refractory diseases is challenging for most physicians. We present two cases of refractory bone edema secondary to complex regional pain syndrome that were successfully treated with a short-term regimen of teriparatide (TPT), a biosynthetic analogue (PTH 1-34) of the human parathormone. The rapid and sustained pain reduction with recovery of knee function for two years following administration of TPT demonstrated its potential for the treatment of bone edema due to complex regional pain syndrome.

show abstract

“…In refractory cases of BME secondary to CRPS, as well as seen for hip osteonecrosis, TPT might be considered as an alternative treatment, although further confirmation is needed [11].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Short-Term Teriparatide for Bone Marrow Edema Secondary to Complex Regional Pain Syndrome: Case Reports on Efficacy After Two Years of Follow-Up

Galluccio¹,

Allam²,

Perdisa³

et al. 2020

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…В настоящее время для лечения этой патологии наиболее широко используют разгрузку пораженного сустава, назначение бисфосфонатов (алендроновая, золендроновая или ибандроновая кислота) в сочетании с препаратами кальция и витамина Д3 [61]. Также для лечения АН применяют терипаратид [63,64], препараты, улучшающие микроциркуляцию и локальное кровообращение [65], антикоагулянты и антиагреганты [66], ударно-волновую терапию и обогащенную тромбоцитами плазму крови [67]. Для снижения интенсивности боли показаны НПВП.…”

Section: дискуссияunclassified

Avascular necrosis of the epiphyses of bones in patients who have had SARS-CoV-2 infection: Clinical observations and a narrative review of literature data

Bialik¹,

Karateev²,

Bialik

et al. 2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The SARS-CoV-2 coronavirus pandemic is a leading medical problem that is in the focus of attention of representatives of all medical specialties. In addition to fighting the COVID-19 infection itself, the task of preventing and treating a wide range of complications arising after the disease is becoming increasingly urgent. One of these complications is avascular necrosis (AN) of bone tissue – a severe pathology that leads to serious suffering, a decrease in the quality of life and disability of patients. For the period from 2020 to 2022 there are 9 reviews in the world literature devoted to the pathogenesis, clinical features and treatment possibilities of this complication. During the same period, 5 articles were published describing clinical observations of AN after suffering COVID-19.The purpose of this work is to demonstrate our own clinical observations, as well as to review the available literature data on the problem of AN after COVID-19 infection. Based on the analysis, it can be concluded that AN after SARS-CoV-2 infection most often develops in the femoral head (>50% of cases), occurs regardless of the severity of the disease and the cumulative dose of glucocorticoids used in the acute period of the disease. It seems advisable to perform an MRI of the hip joints at least once every 3 months for all patients who have had COVID-19 in severe and moderate form during the first year after convalescence.

show abstract

Effects of Teriparatide versus Salmon Calcitonin Therapy for the Treatment of Osteoporosis in Asia: A Meta-analysis of Randomized Controlled Trials

Chen

Al-Qwbani

Zhao

et al. 2021

EMIDDT

View full text Add to dashboard Cite

Objective: The objective of this meta-analysis was to compare the efficacy and safety of teriparatide versus salmon calcitonin for the treatment of osteoporosis in Asian patients and to investigate whether the results of global studies could be applicable to Asian patients. Methods: PubMed, OVID, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE up to December 2018 were searched. Eligible randomized controlled trials (RCTs) that compared teriparatide versus salmon calcitonin in Asian osteoporosis popula-tion were included. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for data synthe-sis, and Cochrane Collaboration software Review Manager 5.3 was used to analyze the pooled data. Results: Three RCTs involving 529 patients were included (mean age 68.7 yr; 93.4% females; mean follow-up 6 months); outcome measures included bone mineral density (BMD) of the femoral neck, total hip and lumbar spine; bone markers and adverse events. We found that the period of 6-months of teriparatide treatment was helpful for the improvement of the BMD of lumbar vertebra, however, the improvement of BMD was not significant in femoral neck and total hip join. There was a positive correlation between bone-specific alka-line phosphatase (BSAP) and osteocalcin (OCN) and the response of Asian patients to subcutaneous injection of 20 micrograms per day of teriparatide. And the proportion of the occurrence of adverse effect was more obvious in teriparatide group compared with salmon calciton-in, but there was no significant difference. Conclusion: Results suggested that the use of teriparatide could improve the lumbar BMD by short-term (six months) application in Asian osteoporosis patients, which is beneficial to the patients who cannot tolerate adverse events of long-term treatment. The BSAP and OCN bone markers could be useful to monitor the responses of Asian osteoporosis patients to teriparatide treatment. Finally, both of teriparatide and salmon calcitonin were well tolerated by Asian patients.

show abstract

Efficacy of Short-term Teriparatide for Hip Osteonecrosis

Cited by 3 publications

References 10 publications

Short-Term Teriparatide for Bone Marrow Edema Secondary to Complex Regional Pain Syndrome: Case Reports on Efficacy After Two Years of Follow-Up

Short-Term Teriparatide for Bone Marrow Edema Secondary to Complex Regional Pain Syndrome: Case Reports on Efficacy After Two Years of Follow-Up

Avascular necrosis of the epiphyses of bones in patients who have had SARS-CoV-2 infection: Clinical observations and a narrative review of literature data

Effects of Teriparatide versus Salmon Calcitonin Therapy for the Treatment of Osteoporosis in Asia: A Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About